Arrowhead Pharmaceuticals, Inc. ARWR
Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) is a cardio-renal-metabolic drug developer. Its lead program, REDEMPLO (plozasiran), is in Phase 3 for familial chylomicronemia syndrome (FCS); sHTG in Phase 3. Its next catalyst on record is zodasiran: YOSEMITE Phase 3 completion (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: zodasiran — YOSEMITE Phase 3 completion (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| REDEMPLO (plozasiran) | FCS | RNA (siRNA/ASO/mRNA) | Approved |
| plozasiran | severe hypertriglyceridemia (SHASTA-3/4/5) | RNA (siRNA/ASO/mRNA) | Phase 3 |
| zodasiran | homozygous familial hypercholesterolemia (YOSEMITE) | RNA (siRNA/ASO/mRNA) | Phase 3 |
| fazirsiran | alpha-1 antitrypsin liver disease | RNA (siRNA/ASO/mRNA) | Phase 3 |
| olpasiran (Amgen) | cardiovascular (Lp(a)) | RNA (siRNA/ASO/mRNA) | Phase 3 |
| ARO-RAGE | pulmonary | RNA (siRNA/ASO/mRNA) | Phase 2 |
| GSK4532990 (GSK) | liver | RNA (siRNA/ASO/mRNA) | Phase 2 |
| daplusiran/tomligisiran (GSK) | hepatitis B | RNA (siRNA/ASO/mRNA) | Phase 2 |
| ARO-INHBE | obesity / MASH | RNA (siRNA/ASO/mRNA) | Phase 2 |
| ARO-ALK7 | obesity / MASH | RNA (siRNA/ASO/mRNA) | Phase 1 |
| ARO-DIMER-PA | ASCVD / mixed hyperlipidemia | RNA (siRNA/ASO/mRNA) | Phase 1 |
| ARO-MAPT | tauopathies / Alzheimer's | RNA (siRNA/ASO/mRNA) | Phase 1 |
Recent results and decisions
- Aug 4, 2026met SHASTA-3 met the primary endpoint of triglyceride reduction vs placebo and all prespecified secondary endpoints; median TG reduction 79% from baseline (pooled SHASTA-3/4: 78% reduction in acute pancreatitis events).
SHASTA-3 and SHASTA-4 successfully met the primary endpoint of triglyceride reduction versus placebo and met all prespecified secondary endpoints in both studies.
Filing - Aug 4, 2026completed enrollment Enrollment completed in the Phase 3 YOSEMITE trial of zodasiran in HoFH (target raised from 60 to 70 patients); trial completion anticipated mid-2027.
The Company anticipates that YOSEMITE will be completed in mid-2027 and, pending successful clinical results, intends to seek regulatory approval in multiple geographies thereafter.
Filing - Aug 4, 2026positive Interim Phase 1/2a data at EASL 2026: ARO-INHBE gave clinically meaningful liver fat reductions as monotherapy and with low-dose tirzepatide in adults with obesity; no figures given.
The interim data demonstrate that ARO-INHBE treatment led to clinically meaningful reductions in liver fat as a monotherapy and in combination with low-dose tirzepatide, a GLP-1/GIP receptor co-agonist, in adults with obesity.
Filing
9 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.